Decitabine treatment for acute myeloid leukemia relapse after allogeneic hematopoietic stem cell transplantation.
Therapeutic options for patients with relapse of acute myeloid leukemia (AML) after allo-SCT are limited. Here, we present a case of a 49-year female with AML who underwent myeloablative allo-SCT from a matched sibling donor. Seven months after transplantation she developed cGVHD and suffered from extramedullary plus concurrent medullary relapse. The presence of CNS extramedullary disease is unique. Our patient was treated with decetabine. After one cycle the patient achieved complete remission and full donor chimerism without severe side effects or the occurrence of GVHD. Our case report, together with previous studies, provides strong evidence that decitabine may be a suitable treatment option for AML relapse after allogeneic transplantation, especially in patients who developed GVHD.
Cancer Center, The First Hospital of Jilin University, Changchun, P.R. China.
X L
XL
Liu
Department of Pediatrics, The First Hospital of Jilin University, Changchun, P.R. China.
X
X
Zhao
Cancer Center, The First Hospital of Jilin University, Changchun, P.R. China.
C
C
Wang
Cancer Center, The First Hospital of Jilin University, Changchun, P.R. China.
S J
SJ
Gao
Cancer Center, The First Hospital of Jilin University, Changchun, P.R. China.
Y H
YH
Tan
D000964:Antimetabolites, Antineoplastic / Q000627:therapeutic use*; D001374:Azacitidine / Q000031:analogs & derivatives* / Q000627:therapeutic use; D000077209:Decitabine; D005260:Female; D006086:Graft vs Host Disease / Q000276:immunology / Q000473:pathology / Q000628:therapy*; D018380:Hematopoietic Stem Cell Transplantation; D006801:Humans; D015470:Leukemia, Myeloid, Acute / Q000276:immunology / Q000473:pathology / Q000628:therapy*; D008875:Middle Aged; D019653:Myeloablative Agonists / Q000627:therapeutic use; D012008:Recurrence; D012074:Remission Induction; D035781:Siblings; D014019:Tissue Donors; D018183:Transplantation Chimera; D014184:Transplantation, Homologous; D016896:Treatment Outcome
D000964:Antimetabolites, Antineoplastic; D019653:Myeloablative Agonists; D000077209:Decitabine; D001374:Azacitidine